Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2010

View Archived Issues

Truvada well tolerated in HIV-1-infected pregnant women and neonates

QNL-111 shown to inhibit HIV-1 DNA integration

Vicriviroc does not meet primary endpoint in two phase III trials in HIV

C5A inhibits HIV-1 and HSV in preclinical studies

Pfizer describes novel kappa opioid receptor antagonists

Novel serotonin 5-HT6 receptor antagonists patented by Janssen

Bristol-Myers Squibb discloses new transcription factor AP-1 inhibitors

Merck KGaA identifies novel PDK1 inhibitors

Ambit Biosciences claims novel Janus kinase inhibitors

Novel dual PI3K alpha and mTOR inhibitors described by S*BIO

Resverlogix activates first site in phase II ASSURE 1 trial of RVX-208 in ACS

Fourth quarter highlights at Merck & Co.

Adeona completes 50% of enrollment in Trimesta trial in multiple sclerosis

GlycoVaxyn begins clinical trial of bioconjugate GVXN-SD-133 Shigella vaccine

Akebia initiates phase Ib trial of AKB-6548 for anemia

Fluticasone nasal spray ineffective in irritant rhinitis in pilot trial

TMTI awards SIGA contract for development broad-spectrum antiviral ST-669

Global Health Ventures to begin European trials of X-Excite for erectile dysfunction

Corcept Therapeutics begins phase I CORT-108297 trial

Rockwell Medical reports phase IIb data on soluble ferric pyrophosphate

Johnson & Johnson reviews fourth quarter of 2009

Actelion reports on BUILD-3 trial of bosentan in idiopathic pulmonary fibrosis

FDA issues refuse to file letter to Adventrx on vinorelbine NDA

Virginia G. Piper Cancer Center and TGen begin phase I trial of Pharmacyclics' PCI-32765 in cancer

FDA grants marketing approval for Shire's VPRIV for type 1 GD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...